Completed
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
NCT02723994· Phase 2· Incyte Corporation· Source
Completed
AMPLATZER™ Amulet™ LAA Occluder Trial
NCT02879448· Abbott Medical Devices· Source
Completed
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01371981· Phase 3· National Cancer Institute (NCI)· Source
Completed
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
NCT01120249· Phase 3· SWOG Cancer Research Network· Source
Completed
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
NCT01231906· Phase 3· Children's Oncology Group· Source
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
NCT01190930· Phase 3· Children's Oncology Group· Source
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
NCT00980460· Phase 3· National Cancer Institute (NCI)· Source
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
NCT00945009· Phase 3· Children's Oncology Group· Source
Completed
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00601900· Phase 3· National Cancer Institute (NCI)· Source
Completed
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00557193· Phase 3· Children's Oncology Group· Source
Completed
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
NCT00336024· Phase 3· Children's Oncology Group· Source
Completed
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
NCT00324805· Phase 3· National Cancer Institute (NCI)· Source
Completed
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
NCT00392327· Phase 3· Children's Oncology Group· Source
Completed
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
NCT00379340· Phase 3· Children's Oncology Group· Source
Completed
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT00408005· Phase 3· National Cancer Institute (NCI)· Source
Completed
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
NCT00352534· Phase 3· Children's Oncology Group· Source
Completed
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
NCT00107198· Phase 2· Children's Oncology Group· Source
Completed
Study of Kidney Tumors in Younger Patients
NCT00898365· Children's Oncology Group· Source
Completed
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
NCT00217737· Phase 3· National Cancer Institute (NCI)· Source
Completed
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
NCT00085735· Phase 3· Children's Oncology Group· Source
Completed
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
NCT00082745· Children's Oncology Group· Source
Completed
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source
Completed
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
NCT00026312· Phase 3· National Cancer Institute (NCI)· Source
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241· Children's Oncology Group· Source